Patient characteristics
| . | n (%) . |
|---|---|
| Male/female | 13/9 |
| Median age, y | 43 (range, 21-61) |
| Underlying disease | |
| Chronic myelogenous leukemia | 4 (18) |
| Acute leukemia | 8 (36) |
| Lymphoma | 3 (14) |
| Multiple myeloma | 6 (27) |
| Other | 1 (5) |
| Disease status | |
| Chronic phase/complete remission | 7 (32) |
| Relapse/refractory | 15 (68) |
| BMT data | |
| Bone marrow is source of graft | 22 (100) |
| Busulfan/cyclophosphamide | 20 (90) |
| Matched-related donor | 20 (90) |
| Matched-unrelated donor | 1 (5) |
| Mismatched-related donor | 1 (5) |
| GVHD prophylaxis | |
| Cyclosporine (CsA) | 13 (59) |
| Tacrolimus (FK-506) | 5 (23) |
| CsA + prednisone/methotrexate | 4 (18) |
| T-cell depletion | 18 (82) |
| Acute GVHD after BMT | 10 (45) |
| Liver involvement | 2 (20) |
| Time from BMT to DLI, d | 309 (range, 73-2617) |
| Date of DLI (4/98-9/01) | |
| 1998 or earlier | 5 (23) |
| 1999–2000 | 9 (41) |
| 2001 | 8 (36) |
| DLI indication | |
| Hematologic relapse | 16 (73) |
| Cytogenetic relapse or preemptive DLI | 6 (27) |
| DLI type | |
| DLI alone | 15 (68) |
| Chemotherapy followed by DLI | 7 (32) |
| Dose of T cells infused | |
| 5 × 107 or fewer | 10 (45) |
| 1 × 108 or more | 12 (55) |
| . | n (%) . |
|---|---|
| Male/female | 13/9 |
| Median age, y | 43 (range, 21-61) |
| Underlying disease | |
| Chronic myelogenous leukemia | 4 (18) |
| Acute leukemia | 8 (36) |
| Lymphoma | 3 (14) |
| Multiple myeloma | 6 (27) |
| Other | 1 (5) |
| Disease status | |
| Chronic phase/complete remission | 7 (32) |
| Relapse/refractory | 15 (68) |
| BMT data | |
| Bone marrow is source of graft | 22 (100) |
| Busulfan/cyclophosphamide | 20 (90) |
| Matched-related donor | 20 (90) |
| Matched-unrelated donor | 1 (5) |
| Mismatched-related donor | 1 (5) |
| GVHD prophylaxis | |
| Cyclosporine (CsA) | 13 (59) |
| Tacrolimus (FK-506) | 5 (23) |
| CsA + prednisone/methotrexate | 4 (18) |
| T-cell depletion | 18 (82) |
| Acute GVHD after BMT | 10 (45) |
| Liver involvement | 2 (20) |
| Time from BMT to DLI, d | 309 (range, 73-2617) |
| Date of DLI (4/98-9/01) | |
| 1998 or earlier | 5 (23) |
| 1999–2000 | 9 (41) |
| 2001 | 8 (36) |
| DLI indication | |
| Hematologic relapse | 16 (73) |
| Cytogenetic relapse or preemptive DLI | 6 (27) |
| DLI type | |
| DLI alone | 15 (68) |
| Chemotherapy followed by DLI | 7 (32) |
| Dose of T cells infused | |
| 5 × 107 or fewer | 10 (45) |
| 1 × 108 or more | 12 (55) |